Cargando…

The Urinary Polyomavirus-Haufen Test: A Highly Predictive Non-Invasive Biomarker to Distinguish “Presumptive” from “Definitive” Polyomavirus Nephropathy: How to Use It—When to Use It—How Does It Compare to PCR Based Assays?

“Definitive” biopsy proven polyomavirus nephropathy (PyVN), usually caused by BK polyomavirus (BKPyV), remains a significant infection of kidney transplants. Diagnosis depends upon an allograft biopsy and outcome depends upon early intervention. Here, we report data on a non-invasive biomarker for P...

Descripción completa

Detalles Bibliográficos
Autores principales: Nickeleit, Volker, Davis, Vicki G., Thompson, Bawana, Singh, Harsharan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833404/
https://www.ncbi.nlm.nih.gov/pubmed/33477927
http://dx.doi.org/10.3390/v13010135
_version_ 1783642057703686144
author Nickeleit, Volker
Davis, Vicki G.
Thompson, Bawana
Singh, Harsharan K.
author_facet Nickeleit, Volker
Davis, Vicki G.
Thompson, Bawana
Singh, Harsharan K.
author_sort Nickeleit, Volker
collection PubMed
description “Definitive” biopsy proven polyomavirus nephropathy (PyVN), usually caused by BK polyomavirus (BKPyV), remains a significant infection of kidney transplants. Diagnosis depends upon an allograft biopsy and outcome depends upon early intervention. Here, we report data on a non-invasive biomarker for PyVN, the urinary PyV-Haufen test. Test results were compared to those of conventional laboratory assays targeting PyV replication, i.e., BKPy-viremia, -viruria and urinary decoy cell shedding. Of 809 kidney transplant recipients, 228 (28%) showed PyV replication with decoy cell shedding and/or BKPy-viremia by quantitative PCR; only a subset of 81/228 (36%) showed “definitive” PyVN. Sensitivity and specificity for identifying patients with PyVN was: 100% and 98%, respectively, urinary PyV-Haufen test; 50% and 54%, respectively, urinary decoy cell shedding; 97% and 32%, respectively, BKPy-viremia with cut-off of ≥250 viral copies/mL; 66% and 80%, respectively, for BKPy-viremia ≥10(4) viral copies/mL. The PyV-Haufen test showed a very strong correlation with the severity of PyVN (Spearman’s ρ = 0.84) and the Banff PyVN disease classes (p < 0.001). In comparison, BKPy-viremia and -viruria levels by PCR displayed modest correlations with PyVN severity (Spearman’s ρ = 0.35 and 0.36, respectively) and were not significantly associated with disease classes. No association was found between decoy cell shedding and PyVN severity or disease classes. Pilot data demonstrated that PyVN resolution with decreasing Banff pvl-scores was reflected by a gradual decrease in PyV-Haufen shedding; such a tight association was not noted for BKPy-viremia. In conclusion, urinary PyV-Haufen testing is a highly specific, non-invasive method to accurately diagnose patients with “definitive” PyVN and to optimize patient management. Assay specifics are discussed.
format Online
Article
Text
id pubmed-7833404
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78334042021-01-26 The Urinary Polyomavirus-Haufen Test: A Highly Predictive Non-Invasive Biomarker to Distinguish “Presumptive” from “Definitive” Polyomavirus Nephropathy: How to Use It—When to Use It—How Does It Compare to PCR Based Assays? Nickeleit, Volker Davis, Vicki G. Thompson, Bawana Singh, Harsharan K. Viruses Article “Definitive” biopsy proven polyomavirus nephropathy (PyVN), usually caused by BK polyomavirus (BKPyV), remains a significant infection of kidney transplants. Diagnosis depends upon an allograft biopsy and outcome depends upon early intervention. Here, we report data on a non-invasive biomarker for PyVN, the urinary PyV-Haufen test. Test results were compared to those of conventional laboratory assays targeting PyV replication, i.e., BKPy-viremia, -viruria and urinary decoy cell shedding. Of 809 kidney transplant recipients, 228 (28%) showed PyV replication with decoy cell shedding and/or BKPy-viremia by quantitative PCR; only a subset of 81/228 (36%) showed “definitive” PyVN. Sensitivity and specificity for identifying patients with PyVN was: 100% and 98%, respectively, urinary PyV-Haufen test; 50% and 54%, respectively, urinary decoy cell shedding; 97% and 32%, respectively, BKPy-viremia with cut-off of ≥250 viral copies/mL; 66% and 80%, respectively, for BKPy-viremia ≥10(4) viral copies/mL. The PyV-Haufen test showed a very strong correlation with the severity of PyVN (Spearman’s ρ = 0.84) and the Banff PyVN disease classes (p < 0.001). In comparison, BKPy-viremia and -viruria levels by PCR displayed modest correlations with PyVN severity (Spearman’s ρ = 0.35 and 0.36, respectively) and were not significantly associated with disease classes. No association was found between decoy cell shedding and PyVN severity or disease classes. Pilot data demonstrated that PyVN resolution with decreasing Banff pvl-scores was reflected by a gradual decrease in PyV-Haufen shedding; such a tight association was not noted for BKPy-viremia. In conclusion, urinary PyV-Haufen testing is a highly specific, non-invasive method to accurately diagnose patients with “definitive” PyVN and to optimize patient management. Assay specifics are discussed. MDPI 2021-01-19 /pmc/articles/PMC7833404/ /pubmed/33477927 http://dx.doi.org/10.3390/v13010135 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nickeleit, Volker
Davis, Vicki G.
Thompson, Bawana
Singh, Harsharan K.
The Urinary Polyomavirus-Haufen Test: A Highly Predictive Non-Invasive Biomarker to Distinguish “Presumptive” from “Definitive” Polyomavirus Nephropathy: How to Use It—When to Use It—How Does It Compare to PCR Based Assays?
title The Urinary Polyomavirus-Haufen Test: A Highly Predictive Non-Invasive Biomarker to Distinguish “Presumptive” from “Definitive” Polyomavirus Nephropathy: How to Use It—When to Use It—How Does It Compare to PCR Based Assays?
title_full The Urinary Polyomavirus-Haufen Test: A Highly Predictive Non-Invasive Biomarker to Distinguish “Presumptive” from “Definitive” Polyomavirus Nephropathy: How to Use It—When to Use It—How Does It Compare to PCR Based Assays?
title_fullStr The Urinary Polyomavirus-Haufen Test: A Highly Predictive Non-Invasive Biomarker to Distinguish “Presumptive” from “Definitive” Polyomavirus Nephropathy: How to Use It—When to Use It—How Does It Compare to PCR Based Assays?
title_full_unstemmed The Urinary Polyomavirus-Haufen Test: A Highly Predictive Non-Invasive Biomarker to Distinguish “Presumptive” from “Definitive” Polyomavirus Nephropathy: How to Use It—When to Use It—How Does It Compare to PCR Based Assays?
title_short The Urinary Polyomavirus-Haufen Test: A Highly Predictive Non-Invasive Biomarker to Distinguish “Presumptive” from “Definitive” Polyomavirus Nephropathy: How to Use It—When to Use It—How Does It Compare to PCR Based Assays?
title_sort urinary polyomavirus-haufen test: a highly predictive non-invasive biomarker to distinguish “presumptive” from “definitive” polyomavirus nephropathy: how to use it—when to use it—how does it compare to pcr based assays?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833404/
https://www.ncbi.nlm.nih.gov/pubmed/33477927
http://dx.doi.org/10.3390/v13010135
work_keys_str_mv AT nickeleitvolker theurinarypolyomavirushaufentestahighlypredictivenoninvasivebiomarkertodistinguishpresumptivefromdefinitivepolyomavirusnephropathyhowtouseitwhentouseithowdoesitcomparetopcrbasedassays
AT davisvickig theurinarypolyomavirushaufentestahighlypredictivenoninvasivebiomarkertodistinguishpresumptivefromdefinitivepolyomavirusnephropathyhowtouseitwhentouseithowdoesitcomparetopcrbasedassays
AT thompsonbawana theurinarypolyomavirushaufentestahighlypredictivenoninvasivebiomarkertodistinguishpresumptivefromdefinitivepolyomavirusnephropathyhowtouseitwhentouseithowdoesitcomparetopcrbasedassays
AT singhharsharank theurinarypolyomavirushaufentestahighlypredictivenoninvasivebiomarkertodistinguishpresumptivefromdefinitivepolyomavirusnephropathyhowtouseitwhentouseithowdoesitcomparetopcrbasedassays
AT nickeleitvolker urinarypolyomavirushaufentestahighlypredictivenoninvasivebiomarkertodistinguishpresumptivefromdefinitivepolyomavirusnephropathyhowtouseitwhentouseithowdoesitcomparetopcrbasedassays
AT davisvickig urinarypolyomavirushaufentestahighlypredictivenoninvasivebiomarkertodistinguishpresumptivefromdefinitivepolyomavirusnephropathyhowtouseitwhentouseithowdoesitcomparetopcrbasedassays
AT thompsonbawana urinarypolyomavirushaufentestahighlypredictivenoninvasivebiomarkertodistinguishpresumptivefromdefinitivepolyomavirusnephropathyhowtouseitwhentouseithowdoesitcomparetopcrbasedassays
AT singhharsharank urinarypolyomavirushaufentestahighlypredictivenoninvasivebiomarkertodistinguishpresumptivefromdefinitivepolyomavirusnephropathyhowtouseitwhentouseithowdoesitcomparetopcrbasedassays